GALR2 and fatty liver disease: Studies have demonstrated that these beneficial effects were eliminated by the GALR2 antagonist M871 in mice fed a high-fat diet and in palmitic acid-induced HepG2 cells, highlighting the critical role of the GALR2 signaling pathway in spexin’s ability to improve fatty liver disease.